161491-32-3

Usage

Uses

Used in Cosmetics Industry:
1-(2,2-diphenylacetyl)-4-Piperidinone is used as an ingredient in skincare products for its antioxidant and anti-inflammatory properties, which contribute to the maintenance of healthy skin and the reduction of inflammation.
Used in Pharmaceutical Industry:
1-(2,2-diphenylacetyl)-4-Piperidinone is used as a potential therapeutic agent for inhibiting the growth of certain cancer cell lines, making it a candidate for cancer treatment research.
Used in Sunscreen Products:
1-(2,2-diphenylacetyl)-4-Piperidinone is used as a UV filter in sunscreen products due to its ability to absorb a wide range of ultraviolet radiation, providing protection against harmful UV rays and reducing the risk of skin damage and skin cancer.

Upstream product

• 1871-76-7 diphenylacetic acid chloride 
• 40064-34-4 piperidine-4,4-diol hydrochloride 
• 40064-34-4 4-piperidone monohydrochloride monohydrate 

Downstream Products

• 292059-40-6 N-(diphenyl)acetyl-4-[4-(carboxymethyl)benzylidene]piperidine 
• 455323-44-1 N-(diphenyl)acetyl-4-[3-(methoxycarbonyl)benzylidene]piperidine 
• 455323-48-5 N-(diphenyl)acetyl-4-[(2-methoxy-4-methoxycarbonyl)benzylidene]piperidine 
• 161491-33-4 N-Diphenylacetyl-4-piperidone-3-carboxaldehyde 

Relevant academic research and scientific papers

Synthesis of N-substituted piperidine-4-(benzylidene-4-carboxylic acids) and evaluation as inhibitors of steroid-5α-reductase type 1 and 2

The synthesis of N-substituted piperidine-4-(benzylidene-4-carboxylic acids) is described [benzoyl (1Scheme 2Synthetic strategy.), benzyl (2), adamantanoyl (3), cyclohexanoyl (4), cyclohexylacetyl (5), diphenylacetyl (6), dicyclohexylacetyl (7), 2-propylpentanoyl (8), diphenylcarbamoyl (9), trimethylacetyl (10), 3,3-dimethylacryloyl (11), dicyclohexylacetyl derivative of the benzyl compound (12)]. Compounds were tested for inhibitory activity toward 5α-reductase isozymes 1 and 2 in human and rat. The test compounds inhibited 5α-reductase, showing a broad range of inhibitory potencies. In rat, compounds 6 (IC50=3.44 and 0.37 μM for type 1 and 2, respectively) and 9 (IC50=0.54 and 0.69 μM for type 1 and 2, respectively) displayed the best inhibition toward both isozymes. Compound 7 showed a strong inhibition toward type 2 human and rat enzyme (IC50=60 and 80 nM) but only a moderate activity versus type 1 enzyme (IC50 approximately 10 μM for rat and human enzyme). In vivo, selected compounds reduced prostate weights in castrated testosterone treated rats. Copyright (C) 2000 Elsevier Science Ltd.

ANGIOTENSION-II RECEPTOR BLOCKING, AZACYCLOALKYL OR AZACYCLOALKENYL

Novel heterocycle substituted azocycloalkane benzylimidazoles of Formula (I), which are useful as angiotensin-II antagonists, are disclosed: STR1